Population pharmacokinetics of rectal theophylline in neonates.
The population pharmacokinetics of theophylline were studied in 35 neonates receiving aminophylline suppositories for the treatment of apnoea of prematurity. Routinely measured theophylline serum concentrations (n = 138, range 3-20 mg/L) were modelled in NONMEM according to a one-compartment model. The influence of a number of clinical and demographic factors, e.g., weight (range 0.8-2.5 kg) and postnatal age (2-80 days), on clearance/bioavailability (CL/F) and volume/bioavailability (V/F) was investigated. Both these parameters were found to significantly correlate to weight alone in a directly proportional manner: CL/F = 40 +/- 2 ml/h/kg and V/F = 1.3 +/- 0.2 L/kg. The absorption was best described by a first-order process, having a half-life of 1.6 +/- 0.7 h. The interindividual variability in CL/F was 25%, whereas the same estimates in V/F and in the first-order absorption rate constant could not be obtained. The residual variability in theophylline concentrations was modelled with additive error with an estimated standard deviation of 1.78 mg/L. From these results, it was concluded that rectal administration of aminophylline in neonates is a therapeutically acceptable alternative to oral administration. The convenience gained by rectal, compared to oral, administrations may compensate, in many instances, for the possibly slightly higher variability in CL/F of the former.
Clinical Pharmacokinetics Laboratory, Stobhill General Hospital, Glasgow, Scotland.
M O
MO
Karlsson
A H
AH
Thomson
E M
EM
McGovern
P
P
Chow
T J
TJ
Evans
A W
AW
Kelman
D000285:Administration, Rectal; D004305:Dose-Response Relationship, Drug; D005260:Female; D014644:Genetic Variation / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn / Q000378:metabolism*; D008297:Male; D008954:Models, Biological; D012044:Regression Analysis; D013806:Theophylline / Q000493:pharmacokinetics*
D013806:Theophylline